Health9 years ago
Novartis Healthcare Private Limited launches Sequadra® Inhaler, an important advance in treatment of COPD
Novartis Healthcare Private Limited (NHPL) announced today the launch of Sequadra® Inhaler (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a...